Remove 2024 Remove Blood Clot Remove Stent
article thumbnail

Philips launches Duo Venous Stent System for Treatment of Symptomatic Venous Outflow Obstruction

DAIC

and an investigator in the VIVID study , which contributed to the device’s FDA approval – successfully used the Duo Venous Stent System for the first time outside of a clinical trial. Duo Hybrid has a distinct integrated design that combines multiple zones of differing mechanical properties into a single stent [3].

Stent 105
article thumbnail

Research Presented at ACC 2024 Found No Reduction in 90-Day Deaths, Heart Attacks With Human Apo/A1

DAIC

milla1cf Sat, 04/06/2024 - 18:32 April 6, 2024 — The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heart attack or stroke within three months of a prior heart attack, according to research presented at the American College of Cardiology ’s Annual Scientific Session.

article thumbnail

Abstract TP214: In-Silico versus In-Vitro Evaluation of a New Stent-Retriever Design: A Novel Approach to Pre-Clinical Device Development

Stroke Journal

Stroke, Volume 55, Issue Suppl_1 , Page ATP214-ATP214, February 1, 2024. In-silico evaluation (computer simulated analysis in a virtual stroke model) has the potential to test and optimize large number of stent-retriever design variations in a relatively time and cost-effective manner.

Stents 40
article thumbnail

The Texas Heart Institute Collaborates on Multi-institutional DOD Grant to Develop Novel Left Ventricular Assist Device

DAIC

As an alternative therapeutic option, LVAD heart pumps have been implanted to help patients with end-stage heart failure sustain blood circulation in the body. However, there are shortcomings associated with LVAD implantation: complications include infection, blood clotting (thrombosis), stroke and bleeding.

article thumbnail

2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and Devices 

Cardiometabolic Health Congress

The first half of 2024 has ushered in a wave of transformative FDA approvals in cardiorenal metabolic health. Edwards EVOQUE Tricuspid Valve Replacement System (Approved: 02/01/2024) This system provides a novel approach to tricuspid valve replacement, potentially benefiting patients with tricuspid regurgitation without open-heart surgery.

article thumbnail

No Reduction in 90-Day Deaths, Heart Attacks With Human Apo/A1, A Building Block of HDL Cholesterol

DAIC

milla1cf Sat, 04/06/2024 - 18:32 April 6, 2024 — The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heart attack or stroke within three months of a prior heart attack, according to research presented at the American College of Cardiology ’s Annual Scientific Session.